Table 2.

Anti-VZV antibody levels in the Active Control group participants without a varicella case, or with a case detected since previous visit or before previous visit until each timepoint (per-protocol cohort for efficacy)

			Anti-VZV ≥25 mIU/mL
Varicella case	Timepoint	N	n	% (95% CI)
No case	Y1	626	50	8 (6–10)
	Y2	529	71	13 (11–17)
	Y4	291	90	31 (26–37)
	Y6	190	105	55 (48–63)
	Y8	151	104	69 (61–76)
	Y10	128	96	75 (67–82)
Case since previous visit	Y1	38	35	92 (79–98)
	Y2	56	55	98 (90–100)
	Y4	134	133	99 (96–100)
	Y6	58	58	100 (94–100)
	Y8	24	24	100 (86–100)
	Y10	11	11	100 (71–100)
Case before previous visit	Y2	38	37	97 (86–100)
	Y4	87	86	99 (94–100)
	Y6	181	181	100 (98–100)
	Y8	267	267	100 (99–100)
	Y10	280	279	100 (98–100)